Janssen Search
Search results
Oncology Affiliates
Our Affiliates in Oncology Considering oncology patients at every stage of their journey We facilitate scientific interchange and collaboration among our extensive worldwide family of companies. The decentralized business model of the Johnson & ...
Thomas M. Luby, Ph.D.
Thomas Luby, Ph.D. is a Senior Director of New Ventures at Johnson & Johnson Innovation, Boston, focusing on early investments and collaborations in Neuroscience, Cardiovascular & Metabolism and Infectious Disease. Prior to joining the Johnson ...
Oncology Partnerships
Partner with Us Seeking Collaborations to Find Cures We are dedicated to collaborating with partners across the globe who share our vision to make cancer a preventable and curable disease by providing transformational therapeutic and diagnostic products ...
BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research
BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research Nov 20, 2018 At a small company in Rockville, Maryland, a handful of researchers are working on viruses that can be tailored to avoid ...
Careers
Your future could be helping us make diseases a thing of the past. John Doe Title--> {{> organisms-social-buttons}} Learn more About Us At Janssen, our employees start each day driven by the belief that patients are waiting and there is no time to ...
Janssen to Highlight Latest Research from Nipocalimab Clinical Development Program to Address Unmet Need in Myasthenia Gravis at AANEM 2023 Meeting
Oct 16, 2023 United States Data presentations reinforce potential for rapid, deep, and sustained efficacy with treatment and demonstrate how the unique immuno-selectivity of the compound may allow for greater targeting across a wide range of autoantibody ...
Janssen Announces Positive Topline Results for JNJ-2113—a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
Jul 04, 2023 United States A greater proportion of patients achieved 100 percent improvement in skin clearance at the highest dose level tested compared to placebo, at week 16 Phase 3 clinical development in moderate-to-severe plaque psoriasis is planned ...
Ann Beliën, Ph.D.
Ann Beliën contributes to development of the Janssen Prevention Center’s discovery portfolio in two main ways. In her Management Team role as Head of Strategy, she is responsible for providing the Global Head of the Janssen Prevention Center with a clear ...
William (Bill) J. Martin, Ph.D.
WILLIAM (BILL) J. MARTIN, PH.D. GLOBAL NEUROSCIENCE THERAPEUTIC AREA HEAD Bill Martin is the Global Neuroscience Therapeutic Area Head at Johnson & Johnson Innovative Medicine and a member of the company’s Group Operating Committee. He leads a ...
Michael Elliott, M.B.B.S., Ph.D., F.R.A.C.P.
As the driver of immunology-focused collaborations out of Johnson & Johnson Innovation, Boston, Michael Elliott, M.B.B.S., Ph.D., F.R.A.C.P. taps into a long-established network of relationships in the Boston area to identify novel and exciting areas ...